Geron Corp (GERN)
4.32
-0.20
(-4.42%)
USD |
NASDAQ |
Jun 26, 10:39
Geron SG&A Expense (TTM): 83.31M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 83.31M |
December 31, 2023 | 69.14M |
September 30, 2023 | 61.58M |
June 30, 2023 | 58.87M |
March 31, 2023 | 49.82M |
December 31, 2022 | 43.63M |
September 30, 2022 | 37.66M |
June 30, 2022 | 29.27M |
March 31, 2022 | 28.89M |
December 31, 2021 | 29.66M |
September 30, 2021 | 28.88M |
June 30, 2021 | 28.14M |
March 31, 2021 | 27.04M |
December 31, 2020 | 25.68M |
September 30, 2020 | 23.85M |
June 30, 2020 | 22.33M |
March 31, 2020 | 21.56M |
December 31, 2019 | 20.89M |
September 30, 2019 | 20.52M |
June 30, 2019 | 19.79M |
March 31, 2019 | 18.84M |
December 31, 2018 | 18.71M |
September 30, 2018 | 19.28M |
June 30, 2018 | 19.78M |
March 31, 2018 | 19.94M |
Date | Value |
---|---|
December 31, 2017 | 19.29M |
September 30, 2017 | 18.59M |
June 30, 2017 | 18.48M |
March 31, 2017 | 18.62M |
December 31, 2016 | 18.76M |
September 30, 2016 | 18.89M |
June 30, 2016 | 18.56M |
March 31, 2016 | 17.99M |
December 31, 2015 | 17.79M |
September 30, 2015 | 17.75M |
June 30, 2015 | 17.49M |
March 31, 2015 | 17.36M |
December 31, 2014 | 16.76M |
September 30, 2014 | 15.90M |
June 30, 2014 | 15.29M |
March 31, 2014 | 14.87M |
December 31, 2013 | 15.62M |
September 30, 2013 | 16.31M |
June 30, 2013 | 17.68M |
March 31, 2013 | 20.08M |
December 31, 2012 | 20.40M |
September 30, 2012 | 21.26M |
June 30, 2012 | 20.25M |
March 31, 2012 | 19.75M |
December 31, 2011 | 23.79M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
19.79M
Minimum
Jun 2019
83.31M
Maximum
Mar 2024
36.52M
Average
28.88M
Median
SG&A Expense (TTM) Benchmarks
Bristol-Myers Squibb Co | 8.377B |
Biomea Fusion Inc | 25.24M |
Ligand Pharmaceuticals Inc | 52.89M |
Asensus Surgical Inc | 34.07M |
Viking Therapeutics Inc | 37.46M |